ClinicalTrials.gg
CompletedNCT01421459ELEMENT 2Updated Dec 18, 2014Results posted

A Study in Adults With Type 2 Diabetes

A Phase 3 interventional study of LY2963016 and Lantus in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
759
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
21st of 175
759 · median 253
Started
2011
with 10 others
Phase 3
60 of 176
1 open now
Registered
94th of 176
by date
Lead sponsor
15 of 176
Eli Lilly and Company

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2011, is one of 60 in phase 3, and was the 94th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes Mellitus based on the disease diagnostic criteria World Health Organization (WHO) classification
  • Have been taking at least 2 types of oral diabetes medications for at least 12 weeks prior to entering the study
  • Have a value greater than or equal to 7.0 percent and less than or equal to 11.0 percent if insulin naive If previously on Lantus, then Hemoglobin A1c must be less than or equal to 11.0 percent
  • Have a of less than or equal to 45 kilogram per meter squared (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have significant liver, cardiac or gastrointestinal disease
  • Have active cancer or have had cancer within the past 5 years (with the exception of basal cell carcinoma or carcinoma in situ)
  • Have an excessive resistance to insulin or to Lantus
  • Have had more than one episode of severe low blood sugar (defined as needing someone else to help because you had very low blood sugar) within the 6 months before entering the study
  • Have taken any other insulin other than Lantus within the past 30 days
  • Taking any other diabetes medicines that are not allowed in the study or not approved to be taken with insulin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
759 participants (actual)

Study arms

  • Experimental
    LY2963016 + OAMs

    LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) \[alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)\] administered per standard of care for 24 weeks

    Drug: LY2963016 · Drug: OAMs

  • Active comparator
    Lantus + OAMs

    Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks

    Drug: Lantus · Drug: OAMs

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.

    Time frame: Baseline, Endpoint (up to 24 weeks)

Secondary outcomes

  1. Change From Baseline in Insulin Antibody Levels

    Blood samples are collected from participants and percentage of insulin antibody binding measured. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline of response and treatment.

    Time frame: Baseline and 4 weeks and 12 weeks and Endpoint (24 weeks and up to 24 weeks)

  2. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.

    Time frame: Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks

  3. 7-Point Self-Monitored Blood Glucose (SMBG) Profiles

    Seven-point SMBG are completed at the following timepoints: Morning (AM) Pre-Meal, Morning (AM) Post-Prandial (PP), Midday (MD) Pre-Meal, Midday PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: Baseline and Endpoint [up to 24 weeks (wk)]

  4. Glycemic Variability of Fasting Blood Glucose

    Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: Baseline and Endpoint (up to 24 weeks)

  5. Change From Baseline in Body Weight

    Change from baseline in body weight. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: Baseline and 4 weeks (wk) and 8 wk and 12 wk and 16 wk and 20 wk and 24 wk and Endpoint (up to 24 wk)

  6. Adult Low Blood Sugar Survey (ALBSS)

    ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score range is 0 to 60 and Worry Total Score range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. The ALBSS Total Scores (Worry and Behavior item scores combined) range is 0 to 132. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: 4 weeks (wk) and 12 wk and Endpoint (up to 24 wk)

  7. Insulin Treatment Satisfaction Questionnaire (ITSQ)

    ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) mean are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: 4 weeks (wk) and 12 wk and Endpoint (EP) (up to 24 wk)

  8. Insulin Dose Per Body Weight (U/kg) Per Day

    Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

    Time frame: Endpoint (up to 24 weeks)

  9. Insulin Dose (Units)

    Units of insulin taken daily. Least Square (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1C, country, sulfonylurea use, time of basal insulin injection and treatment.

    Time frame: Endpoint (up to 24 weeks)

  10. Percentage of Participants With HbA1c <7 % and HbA1c ≤6.5%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks and Endpoint (up to 24 weeks)

  11. Incidence of Hypoglycemic Events

    A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤70 milligrams/deciliter (mg/dL) even if it was not associated with signs, symptoms, or treatment consistent with current American Diabetes Association (ADA: 2005) guidelines. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.

    Time frame: Baseline and Endpoint (up to 24 weeks)

  12. Rate Per 30 Days of Hypoglycemic Events

    The rate of hypoglycemic events per 30 days between two visits is defined as the total number of events between the visits divided by the actual number of days between the visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

    Time frame: Baseline, Endpoint (up to 24 weeks)

Other outcomes

  1. Percentage of Participants With Detectable Insulin Antibody Levels

    Time frame: Baseline and 4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)

  2. Percentage of Participants With Treatment Emergent Antibody Response (TEAR)

    TEAR is defined as an absolute increase of at least 1% in insulin antibody levels (measured in % binding) and at least 30% relative increase from Baseline for participants who are insulin antibody-positive at Baseline, or turning from insulin antibody-negative status at Baseline to antibody-positive during the course of the study following treatment with study drug.

    Time frame: 4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)

07

Results

Posted Oct 9, 2014

Participant flow

Participant flow — Overall Study
MilestoneLY2963016 + OAMsLantus + OAMs
Started379380
Received at least 1 dose of study drug376380
Completed334328
Not completed4552
Withdrew: Adverse event610
Withdrew: Death11
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up89
Withdrew: Physician decision99
Withdrew: Protocol violation85
Withdrew: Withdrawal by subject1216

Outcome measures

PrimaryChange From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.

Time frame:
Baseline, Endpoint (up to 24 weeks)
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)
percentage of glycosylated hemoglobinLY2963016 + OAMsLantus + OAMs
Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)-1.286 ± 0.06-1.338 ± 0.06
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.403 · Mean difference (final values): 0.052 · 95% CI -0.070 to 0.175
SecondaryChange From Baseline in Insulin Antibody Levels

Blood samples are collected from participants and percentage of insulin antibody binding measured. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline of response and treatment.

Time frame:
Baseline and 4 weeks and 12 weeks and Endpoint (24 weeks and up to 24 weeks)
Reported as:
Least squares mean · percentage of insulin antibody binding
Change From Baseline in Insulin Antibody Levels
percentage of insulin antibody bindingLY2963016 + OAMsLantus + OAMs
Change at 4 weeks (n=10, 3)-1.07 ± 1.47-3.25 ± 2.79
Change at 12 weeks (n=9, 5)-1.57 ± 1.14-4.39 ± 1.54
Change at 24 weeks (n=10, 2)-2.61 ± 0.60-3.21 ± 1.35
Change at Endpoint, up to 24 weeks (n=14, 6)-2.49 ± 0.39-3.11 ± 0.06
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.

Time frame:
Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cLY2963016 + OAMsLantus + OAMs
Change at 4 weeks (n=368, 371)-0.452 ± 0.03-0.481 ± 0.03
Change at 8 weeks (n=359, 358)-0.871 ± 0.05-0.866 ± 0.05
Change at 12 weeks (n=349, 351)-1.134 ± 0.06-1.143 ± 0.06
Change at 16 weeks (n=345, 345)-1.265 ± 0.06-1.321 ± 0.06
Change at 20 weeks (n=338, 334)-1.294 ± 0.06-1.379 ± 0.06
Change at 24 weeks (n=331, 329)-1.336 ± 0.06-1.438 ± 0.06
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.382 (P-value is for 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.910 (P-value is for 8 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.869 (P-value is for 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.345 (P-value is for 16 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.161 (P-value is for 20 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.097 (P-value is for 24 weeks.)
Secondary7-Point Self-Monitored Blood Glucose (SMBG) Profiles

Seven-point SMBG are completed at the following timepoints: Morning (AM) Pre-Meal, Morning (AM) Post-Prandial (PP), Midday (MD) Pre-Meal, Midday PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
Baseline and Endpoint [up to 24 weeks (wk)]
Reported as:
Least squares mean · millimoles per liter (mmol/L)
7-Point Self-Monitored Blood Glucose (SMBG) Profiles
millimoles per liter (mmol/L)LY2963016 + OAMsLantus + OAMs
Baseline- AM Pre-Meal (n=353, 359)8.82 ± 0.138.86 ± 0.13
Baseline- AM 2 hrs PP (n=356, 356)11.68 ± 0.1611.80 ± 0.16
Baseline- MD Pre-Meal (n=357, 357)9.09 ± 0.159.44 ± 0.15
Baseline- MD 2 hrs PP (n=357, 353)10.65 ± 0.1510.89 ± 0.15
Baseline- EV Pre-Meal (n=356, 354)9.29 ± 0.159.59 ± 0.15
Baseline- Bed Time (n=355, 354)11.25 ± 0.1611.17 ± 0.16
Baseline- 0300 hrs (n=342, 341)8.83 ± 0.158.96 ± 0.15
Endpoint, up to 24 wk- AM Pre-Meal (n=353, 359)5.94 ± 0.116.06 ± 0.11
Endpoint, up to 24 wk- AM 2 hrs PP (n=356, 356)8.07 ± 0.178.40 ± 0.17
Endpoint, up to 24 wk- MD Pre-Meal (n=357, 357)6.81 ± 0.157.12 ± 0.15
Endpoint, up to 24 wk- MD 2 hrs PP (n=357, 353)8.53 ± 0.178.69 ± 0.18
Endpoint, up to 24 wk- EV Pre-Meal (n=356, 354)7.29 ± 0.167.40 ± 0.16
Endpoint, up to 24 wk- Bed Time (n=355, 354)8.56 ± 0.188.67 ± 0.18
Endpoint, up to 24 wk- 0300 hrs (n=342, 341)6.72 ± 0.156.70 ± 0.15
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.837 (P-value is at Morning Pre-Meal at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.620 (P-value is for Morning 2 hrs PP Meal at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.107 (P-value is for Midday Pre-Meal at Baseline)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.258 (P-value is for Midday 2 hrs PP Meal at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.161 (P-value is for Evening Pre-Meal at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.725 (P-value is for Bed Time at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.543 (P-value is for 0300 hrs at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.265 (P-value is for Morning Pre-Meal at Endpoint, up to 24 wk.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.050 (P-value is for Morning 2 hrs PP Meal at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.040 (P-value is for Midday Pre-Meal at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.366 (P-value is for Midday 2 hrs PP Meal at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.485 (P-value is for Evening Pre-Meal at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.537 (P-value is for Bed Time at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.878 (P-value is for 0300 hrs at Endpoint, up to 24 weeks.)
SecondaryGlycemic Variability of Fasting Blood Glucose

Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
Baseline and Endpoint (up to 24 weeks)
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Glycemic Variability of Fasting Blood Glucose
millimoles per liter (mmol/L)LY2963016 + OAMsLantus + OAMs
Baseline1.18 ± 0.051.20 ± 0.05
Endpoint, up to 24 weeks0.81 ± 0.060.79 ± 0.06
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.779 (P-value is for Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.788 (P-value is for Endpoint, up to 24 weeks.)
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
Baseline and 4 weeks (wk) and 8 wk and 12 wk and 16 wk and 20 wk and 24 wk and Endpoint (up to 24 wk)
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)LY2963016 + OAMsLantus + OAMs
Change at 4 wk (n=361, 364)0.292 ± 0.110.526 ± 0.11
Change at 8 wk (n=358, 357)0.999 ± 0.161.152 ± 0.16
Change at 12 wk (n=350, 352)1.271 ± 0.191.440 ± 0.19
Change at 16 wk (n=342, 344)1.550 ± 0.221.918 ± 0.22
Change at 20 wk (n=340, 333)1.734 ± 0.252.234 ± 0.25
Change at 24 wk (n=335, 329)1.914 ± 0.272.175 ± 0.27
Change at Endpoint, up to 24 wk (n=370, 374)1.776 ± 0.252.020 ± 0.25
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.687 (P-value is for Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.036 (P-value is for change at 4 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.323 (P-value is for change at 8 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.368 (P-value is for change at 12 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.089 (P-value is for change at 16 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.041 (P-value is for change at 20 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.330 (P-value is for change at 24 wks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.334 (P-value is for change at Endpoint, up to 24 wks.)
SecondaryAdult Low Blood Sugar Survey (ALBSS)

ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score range is 0 to 60 and Worry Total Score range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. The ALBSS Total Scores (Worry and Behavior item scores combined) range is 0 to 132. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
4 weeks (wk) and 12 wk and Endpoint (up to 24 wk)
Reported as:
Least squares mean · units on a scale
Adult Low Blood Sugar Survey (ALBSS)
units on a scaleLY2963016 + OAMsLantus + OAMs
Behavior Score- 4 wk (n=351, 354)8.41 ± 0.638.64 ± 0.64
Behavior Score- 12 wk (n=350, 349)8.95 ± 0.629.36 ± 0.62
Behavior Score- Endpoint up to 24 wk (n=368, 371)7.90 ± 0.608.36 ± 0.60
Worry Score- 4 wk (n=352, 354)7.74 ± 0.918.82 ± 0.92
Worry Score- 12 wk (n=349, 348)8.35 ± 0.918.51 ± 0.91
Worry Score- Endpoint up to 24 wk (n=368, 371)8.61 ± 0.898.57 ± 0.90
ALBSS Total Score- 4 wk (n=352, 354)16.15 ± 1.2917.45 ± 1.29
ALBSS Total Score- 12 wk (n=349, 348)17.32 ± 1.3217.85 ± 1.32
ALBSS Total Score-Endpoint up to 24 wk (n=368,371)16.53 ± 1.3216.92 ± 1.33
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.726 (P-value is for Behavior domain at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.502 (P-value is for Behavior domain at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.437 (P-value is for Behavior domain at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.237 (P-value is for Worry domain at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.860 (P-value is for Worry domain at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.966 (P-value is for Worry domain at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.313 (P-value is for ALBSS Total Score at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.683 (P-value is for ALBSS Total Score at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.765 (P-value is for ALBSS Total Score at Endpoint, up to 24 weeks.)
SecondaryInsulin Treatment Satisfaction Questionnaire (ITSQ)

ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) mean are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
4 weeks (wk) and 12 wk and Endpoint (EP) (up to 24 wk)
Reported as:
Least squares mean · units on a scale
Insulin Treatment Satisfaction Questionnaire (ITSQ)
units on a scaleLY2963016 + OAMsLantus + OAMs
IR- 4 wk (n=352, 354)86.10 ± 1.2486.12 ± 1.25
IR- 12 wk (n=350, 348)83.44 ± 1.2584.54 ± 1.25
IR- EP, up to 24 wk (n=368, 371)85.62 ± 1.3185.21 ± 1.32
LF- 4 wk (n=352, 354)79.65 ± 1.5579.87 ± 1.55
LF-12 wk (n=350, 350)76.69 ± 1.5278.16 ± 1.52
LF- EP, up to 24 wk (n=368, 372)78.00 ± 1.5178.32 ± 1.52
HC- 4 wk (n=352, 354)79.36 ± 1.4680.33 ± 1.46
HC- 12 wk (n=350, 348)77.15 ± 1.4977.73 ± 1.49
HC- EP, up to 24 wk (n=368, 372)77.51 ± 1.5479.08 ± 1.55
GC- 4 wk (n=352, 354)75.67 ± 1.6275.47 ± 1.63
GC- 12 wk (n=350, 347)78.95 ± 1.5381.38 ± 1.53
GC- EP, up to 24 wk (n=368, 372)80.74 ± 1.5380.26 ± 1.54
IDD- 4 wk (n=352, 353)70.56 ± 1.5673.22 ± 1.56
IDD- 12 wk (n=348, 349)70.97 ± 1.7072.21 ± 1.69
IDD- EP, up to 24 wk (n=368, 372)72.85 ± 1.6373.87 ± 1.64
ITSQ Overall Total- 4 wk (n=352, 354)78.02 ± 1.1278.98 ± 1.12
ITSQ Overall Total- 12 wk (n=349, 348)77.06 ± 1.2178.30 ± 1.20
ITSQ Overall Total- EP, up to 24 wk (n=368, 372)78.54 ± 1.2179.06 ± 1.22
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.983 (P-value is for Inconvenience of Regimen at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.371 (P-value is for Inconvenience of Regimen at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.757 (P-value is for Inconvenience of Regimen at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.890 (P-value is for Lifestyle Flexibility at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.326 (P-value is for Lifestyle Flexibility at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.831 (P-value is for Lifestyle Flexibility at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.507 (P-value is for Hypoglycemic Control at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.690 (P-value is for Hypoglycemic Control at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.307 (P-value is for Hypoglycemic Control at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.902 (P-value is for Glycemic Control at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.109 (P-value is for Glycemic Control at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.754 (P-value is for Glycemic Control at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.088 (P-value is for Insulin Deliver Device at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.456 (P-value is for Insulin Delivery Device at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.531 (P-value is for Insulin Delivery Device at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.393 (P-value is for ITSQ Total Score at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.296 (P-value is for ITSQ Total Score at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.662 (P-value is for ITSQ Total Score at Endpoint, up to 24 weeks.)
SecondaryInsulin Dose Per Body Weight (U/kg) Per Day

Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.

Time frame:
Endpoint (up to 24 weeks)
Reported as:
Least squares mean · units per kilogram per day (U/kg/day)
Insulin Dose Per Body Weight (U/kg) Per Day
units per kilogram per day (U/kg/day)LY2963016 + OAMsLantus + OAMs
Insulin Dose Per Body Weight (U/kg) Per Day0.500 ± 0.030.479 ± 0.03
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANCOVA · p = 0.393
SecondaryInsulin Dose (Units)

Units of insulin taken daily. Least Square (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1C, country, sulfonylurea use, time of basal insulin injection and treatment.

Time frame:
Endpoint (up to 24 weeks)
Reported as:
Least squares mean · units per day (U/day)
Insulin Dose (Units)
units per day (U/day)LY2963016 + OAMsLantus + OAMs
Insulin Dose (Units)44.465 ± 2.6241.015 ± 2.61
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · ANOVA · p = 0.185 (P-value is for Insulin Dose at Endpoint, up to 24 weeks.)
SecondaryPercentage of Participants With HbA1c <7 % and HbA1c ≤6.5%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks and Endpoint (up to 24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7 % and HbA1c ≤6.5%
percentage of participantsLY2963016 + OAMsLantus + OAMs
HbA1c- at Baseline < 7.0 % (n=369, 375)6.27.2
HbA1c- at Baseline ≤ 6.5% (n=369, 375)3.52.4
HbA1c- at 4 weeks < 7% (n=368, 371)16.615.4
HbA1c- at 4 week ≤ 6.5%(n=368, 371)5.75.9
HbA1c- at 8 weeks < 7% (n=359, 358)27.029.9
HbA1c- at 8 weeks ≤ 6.5% (n=359, 358)10.314.5
HbA1c- at 12 weeks <7% (n=349, 351)39.343.0
HbA1c- at 12 weeks ≤ 6.5% (n=349, 351)20.322.8
HbA1c- at 16 weeks <7% (n=345, 345)46.752.8
HbA1c- at 16 weeks ≤ 6.5% (n=345, 345)24.328.4
HbA1c- at 20 weeks < 7% (n=338, 334)49.454.2
HbA1c- at 20 weeks ≤ 6.5% (n=338, 334)26.632.6
HbA1c- at 24 weeks < 7% (n=331, 329)50.855.9
HbA1c- at 24 weeks ≤ 6.5% (n=331, 329)27.532.5
HbA1c- Endpoint, up to 24 weeks <7% (n=369, 375)48.852.5
HbA1c- Endpoint, up to 24 weeks ≤ 6.5% (n=369,375)26.830.4
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.661 (P-value is for HbA1c \<7% at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.394 (P-value is for HbA1c ≤ 6.5% at Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.688 (P-value is for HbA1c \<7% at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = >0.999 (P-value is for HbA1c ≤ 6.5% at 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.409 (P-value is for HbA1c \<7% at 8 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.090 (P-value is for HbA1c ≤ 6.5% at 8 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.319 (P-value is for HbA1c \<7% at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.463 (P-value is for HbA1c ≤6.5% at 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.128 (P-value is for HbA1c \<7% at 16 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.261 (P-value is for HbA1c ≤6.5% at 16 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.218 (P-value is for HbA1c \<7% at 20 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.092 (P-value is for HbA1c ≤6.5% at 20 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.186 (P-value is for HbA1c \<7%% at 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.174 (P-value is for HbA1c ≤6.5% at 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.340 (P-value is for HbA1c \<7% at Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.293 (P-value is for HbA1c ≤6.5% at Endpoint, up to 24 weeks.)
SecondaryIncidence of Hypoglycemic Events

A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤70 milligrams/deciliter (mg/dL) even if it was not associated with signs, symptoms, or treatment consistent with current American Diabetes Association (ADA: 2005) guidelines. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.

Time frame:
Baseline and Endpoint (up to 24 weeks)
Reported as:
Number · hypoglycemic events in 24 weeks
Incidence of Hypoglycemic Events
hypoglycemic events in 24 weeksLY2963016 + OAMsLantus + OAMs
Total Events with BG ≤70 mg/dL35643845
Severe Events72
Nocturnal Events with BG ≤70 mg/dL12481386
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.594 (P-value is for Total Hypoglycemic with BG ≤70 mg/dL events.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.462 (P-value is for Nocturnal Hypoglycemic with BG ≤70 mg/dL events.)
SecondaryRate Per 30 Days of Hypoglycemic Events

The rate of hypoglycemic events per 30 days between two visits is defined as the total number of events between the visits divided by the actual number of days between the visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

Time frame:
Baseline, Endpoint (up to 24 weeks)
Reported as:
Mean · hypoglycemic events per 30 days
Rate Per 30 Days of Hypoglycemic Events
hypoglycemic events per 30 daysLY2963016 + OAMsLantus + OAMs
Total Hypoglycemia with BG ≤70 mg/dL1.75 ± 2.001.83 ± 2.32
Severe Hypoglycemia0.00 ± 0.050.00 ± 0.01
Nocturnal Hypoglycemia with BG ≤70 mg/dL0.61 ± 0.960.66 ± 1.20
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · Wilcoxon (Mann-Whitney) · p = 0.995 (P-value is for Total Hypoglycemia with BG ≤70 mg/dL events.)
  • LY2963016 + OAMs vs Lantus + OAMs · Wilcoxon (Mann-Whitney) · p = 0.686 (P-value is for Nocturnal Hypoglycemia with BG ≤70 mg/dL events.)
Other pre-specifiedPercentage of Participants With Detectable Insulin Antibody Levels
Time frame:
Baseline and 4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Detectable Insulin Antibody Levels
percentage of participantsLY2963016 + OAMsLantus + OAMs
Baseline (n=365, 365)5.53.6
4 weeks (n=362, 359)7.23.6
12 weeks (n= 351, 344)7.16.7
24 weeks (n=337, 328)8.65.8
Endpoint, up to 24 weeks (n= 365, 365)8.26.0
Baseline to 24 weeks (Overall) (n= 365, 365)15.311.0
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.285 (P-value is for Baseline.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.047 (P-value is for 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.882 (P-value is for 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.179 (P-value is for 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.314 (P-value is for Endpoint, up to 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.100 (P-value is for Baseline to 24 weeks (Overall).)
Other pre-specifiedPercentage of Participants With Treatment Emergent Antibody Response (TEAR)

TEAR is defined as an absolute increase of at least 1% in insulin antibody levels (measured in % binding) and at least 30% relative increase from Baseline for participants who are insulin antibody-positive at Baseline, or turning from insulin antibody-negative status at Baseline to antibody-positive during the course of the study following treatment with study drug.

Time frame:
4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Antibody Response (TEAR)
percentage of participantsLY2963016 + OAMsLantus + OAMs
4 weeks (n= 362, 359)5.02.8
12 weeks (n= 351, 344)5.15.2
24 weeks (n=337, 328)6.25.2
Endpoint, up to 24 weeks (n= 365, 365)6.05.5
Overall (n= 365, 365)12.39.3
Statistical analysis
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.176 (P-value is for 4 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.999 (P-value is for 12 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.618 (P-value is for 24 weeks.)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = 0.874 (P-value is for Endpoint (LOCF).)
  • LY2963016 + OAMs vs Lantus + OAMs · Chi-squared · p = >0.233 (P-value is for Overall (Baseline to 24 weeks).)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016 + OAMs—15/376 (4%)188/376 (50%)
Lantus + OAMs—18/380 (4.7%)175/380 (46.1%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventLY2963016 + OAMsLantus + OAMs
Coronary artery diseaseCardiac disorders1/3763/380
HypoglycaemiaMetabolism and nutrition disorders2/3763/380
PregnancyPregnancy, puerperium and perinatal conditions0/1971/181
Cardiac failure congestiveCardiac disorders1/3760/380
Coeliac diseaseGastrointestinal disorders1/3760/380
Intestinal obstructionGastrointestinal disorders1/3760/380
CholecystitisHepatobiliary disorders1/3760/380
BronchitisInfections and infestations1/3761/380
CellulitisInfections and infestations1/3761/380
Clostridial infectionInfections and infestations1/3760/380
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLY2963016 + OAMsLantus + OAMs
NasopharyngitisInfections and infestations21/37622/380
Upper respiratory tract infectionInfections and infestations19/37615/380
DiarrhoeaGastrointestinal disorders9/37614/380
InfluenzaInfections and infestations7/37611/380
Abnormal weight gainMetabolism and nutrition disorders10/3763/380
Back painMusculoskeletal and connective tissue disorders9/37610/380
NauseaGastrointestinal disorders8/3768/380
SinusitisInfections and infestations8/3763/380
HeadacheNervous system disorders8/3766/380
CoughRespiratory, thoracic and mediastinal disorders8/3768/380

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)LY2963016 + OAMsLantus + OAMsTotal
Mean58.98 ± 10.1758.67 ± 10.0258.82 ± 10.09
Sex: Female, Male
Sex: Female, Male(Participants)LY2963016 + OAMsLantus + OAMsTotal
Female197181378
Male179199378
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2963016 + OAMsLantus + OAMsTotal
Hispanic or Latino106104210
Not Hispanic or Latino244256500
Unknown or Not Reported262046
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2963016 + OAMsLantus + OAMsTotal
American Indian or Alaska Native172138
Asian293564
Native Hawaiian or Other Pacific Islander000
Black or African American263258
White302291593
More than one race213
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)LY2963016 + OAMsLantus + OAMsTotal
Czech Republic181836
France8816
Germany151328
Greece101222
Hungary323062
Italy6511
Korea, Republic of171532
Mexico292958
Poland121123
Puerto Rico393170
Spain101222
Taiwan91221
United States171184355
Baseline Hemoglobin A1c (HbA1c)
Baseline Hemoglobin A1c (HbA1c)(percentage of glycosylated hemoglobin)LY2963016 + OAMsLantus + OAMsTotal
Mean8.34 ± 1.098.31 ± 1.068.33 ± 1.08
Sulfonylurea Use
Sulfonylurea Use(participants)LY2963016 + OAMsLantus + OAMsTotal
Yes, did use sulfonylurea315315630
No, did not use sulfonylurea6165126
Time of Basal Insulin Injection
Time of Basal Insulin Injection(participants)LY2963016 + OAMsLantus + OAMsTotal
Daytime187188375
Evening/Bedtime189192381

1 further baseline measures are reported on the registry.

08

Study locations

62 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montgomery, Alabama 36106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brooksville, Florida 34601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Port Richey, Florida 34652, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oviedo, Florida 32765, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pembroke Pines, Florida 33028, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30329, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roswell, Georgia 30076, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Des Moines, Iowa 50314, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Port Gibson, Mississippi 39150, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Missouri 65807, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mineola, New York 11501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Hyde Park, New York 11040, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Syracuse, New York 13210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Asheville, North Carolina 28803, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salisbury, North Carolina 28144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fargo, North Dakota 58103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19107, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77074, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hurst, Texas 76054, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Longview, Texas 75605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plano, Texas 75093, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brandys Nad Labem, 250 01, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 15500, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44300, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vieux Conde, 59690, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aschaffenburg, 63739, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01219, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Giengen, 89537, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22607, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, 69115, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lüneburg, 21339, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Ingbert-Oberwürzbach, 66386, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 57010, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1171, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Papa, 8500, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 139-872, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulsan-Si, 682-714, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara Jalisco, 04460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 03300, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64710, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampico, 89000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-404, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-858, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ruda Slaska, 41-709, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-403, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carolina, 00983, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00917-3104, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00909, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Málaga, 29006, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palma De Mallorca, 07014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Teruel, 44001, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 404, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11031, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yong Kung City, 71004, Taiwan
09

References and documents

Publications

  • Nishiyama H, Shingaki T, Suzuki Y, Ilag LL. Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus(R) Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation. Diabetes Ther. 2018 Aug;9(4):1469-1476. doi: 10.1007/s13300-018-0450-0. Epub 2018 May 31. PubMed 29855972 ↗
  • Pollom RK, Costigan T, Lacaya LB, Ilag LL, Hollander PA. Similar Efficacy and Safety of Basaglar(R) and Lantus(R) in Patients with Type 2 Diabetes in Age Groups (< 65 Years, >/= 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study. Diabetes Ther. 2018 Apr;9(2):827-837. doi: 10.1007/s13300-018-0405-5. Epub 2018 Mar 14. PubMed 29542012 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 1 month after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2011
First posted
Aug 22, 2011
Start
Sep 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Jan 11, 2013
Results first posted
Oct 9, 2014
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01421459
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Sep 2011
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Oct 9, 2014
Last update
Dec 18, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion